Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Non Operating Income (2022 - 2024)

Indivior Pharmaceuticals has reported Non Operating Income over the past 3 years, most recently at -$9.0 million for Q4 2024.

  • For Q4 2024, Non Operating Income fell 1000.0% year-over-year to -$9.0 million; the TTM value through Dec 2024 reached -$19.0 million, down 480.0%, while the annual FY2024 figure was -$20.0 million, 500.0% down from the prior year.
  • Non Operating Income for Q4 2024 was -$9.0 million at Indivior Pharmaceuticals, down from -$5.0 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $2.0 million in Q4 2022 and troughed at -$9.0 million in Q4 2024.
  • A 3-year average of -$1.7 million and a median of -$2.0 million in 2022 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: surged 200.0% in 2023 and later tumbled 1000.0% in 2024.
  • Year by year, Non Operating Income stood at $2.0 million in 2022, then plummeted by 50.0% to $1.0 million in 2023, then tumbled by 1000.0% to -$9.0 million in 2024.
  • Business Quant data shows Non Operating Income for INDV at -$9.0 million in Q4 2024, -$5.0 million in Q3 2024, and -$3.0 million in Q2 2024.